Results 61 to 70 of about 2,457 (125)

Data accuracy in the European Cystic Fibrosis Society Patient Registry: results of an on-site data validation project. [PDF]

Orphanet J Rare Dis
Lutz N, Alice F, Marko K, Nadine W, Mayor SL, Anna Z, Vibha P, ECFS Patient Registry Steering Group.   +7 more
europepmc   +1 more source

Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Respir Res
Mouchtaridi E, Kowalik A, Raineri EJM, Humbert M, Jägerstedt J, Bojarlind M, Nilsson K, Flodström-Tullberg M, Pincikova T, Sandberg JK.   +9 more
europepmc   +1 more source

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapies on Liver Transplant Outcomes. [PDF]

Gastro Hep Adv
Naimimohasses S, Ray A, Tan E, Wiggins A, Hasjim BJ, Chen S, Bhat M.   +6 more
europepmc   +1 more source

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase-1 in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Sankararaman S, Prunty L, Pamer C, Thavamani A, Roesch E, Schindler T.   +5 more
europepmc   +1 more source

Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review. [PDF]

Clin Pharmacokinet
Elzinga FA, Malik PRV, Akkerman OW, Rottier BL, van der Vaart H, Touw DJ, Koppelman GH, Mian P.   +7 more
europepmc   +1 more source

Inflammatory response in CF airway epithelial cells: a comparative study of modulators and wild-type CFTR rescue. [PDF]

Front Pharmacol
Kouadri A, Lyko C, El Hajjar C, Cormenier J, Kevin Gemy K, Alfaidy N, Benharouga M.   +6 more
europepmc   +1 more source

Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients-a systematic review. [PDF]

Front Pediatr
Pietrzykowska A, Darmoń J, Szymocha K, Donocik W, Tarasiewicz M, Stadnik J, Jarosz-Chobot P.   +6 more
europepmc   +1 more source

Reflection confocal microscopy for quantitative assessment of airway surface layer dysregulation and pharmacological rescue in cystic fibrosis under near-physiological conditions. [PDF]

Sci Rep
Agircan AS, Lampe M, Scheuermann H, Albrecht T, Graeber SY, Balázs A, Baumann I, Block S, Pepperkok R, Mall MA, Duerr J.   +10 more
europepmc   +1 more source

Variation in Use of Lumacaftor/Ivacaftor [PDF]

D37. A PULMONARY AND CRITICAL CARE MEDLEY, 2020
openaire   +1 more source

Repurposing FDA-approved drugs and natural compounds to inhibit the RNA-dependent RNA polymerase domain of dengue virus 2 or dengue virus 3. [PDF]

Sci Rep
Ahmadi K, Jahantigh HR, Ahmadi N, Shahbazi B.   +3 more
europepmc   +1 more source